Targeted breakage of paracentromeric heterochromatin induces chromosomal instability.
Current models suggest that genomic instability is crucial in the accumulation of the multiple alterations required for tumorigenesis. However, the nature of the initial damage responsible for the origin of genomic instability remains poorly understood. In this investigation we demonstrate that the nucleotide analog 2,6-diaminopurine (DAP) can be used to induce highly focused damage to the large blocks of paracentromeric heterochromatin on chromosomes 1, 9 and 16. A large fraction of cells exposed to DAP exhibit undercondensation of alpha and classical heterochromatin which persists into metaphase. Subsequent chromosome breakage was observed for one of the target chromosomes by preferential exclusion of chromosome 16 fragments into micronuclei (P < 0.0001). The specificity of DAP-induced chromosomal breakage enabled us to utilize it as a reagent to demonstrate that paracentromeric heterochromatin is a sensitive target for the induction of persistent genomic instability. We observed a 100-fold increase in mutagenesis affecting a chromosome 16 marker (APRT) compared with marker loci on chromosomes 17 (TK) or X (HPRT). We previously reported that APRT- mutants were recovered at a high rate upon selection in DAP in a process involving recombinationally mediated loss of heterozygosity that extends from the telomere to the boundary region of the paracentromeric heterochromatin. Karyotypic analysis of DAP-resistant APRT- mutant clones demonstrated extensive genomic instability, particularly evidence of multiple and sequential events affecting chromosome 16. These data suggest that the heterochromatic breakage observed cytogenetically immediately following DAP exposure is also responsible for the initiation of persistent genomic instability.
Smith
L E
LE
Environmental Toxicology Graduate Program, University of California, Riverside 92521, USA.
Parks
K K
KK
Hasegawa
L S
LS
Eastmond
D A
DA
Grosovsky
A J
AJ
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000633:toxicity; D000228:Adenine Phosphoribosyltransferase / Q000235:genetics; D001374:Azacitidine / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects / Q000648:ultrastructure; D002460:Cell Line; D002503:Centromere / Q000187:drug effects / Q000648:ultrastructure; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000187:drug effects / Q000648:ultrastructure; D002885:Chromosomes, Human, Pair 16 / Q000187:drug effects / Q000648:ultrastructure; D002886:Chromosomes, Human, Pair 17 / Q000187:drug effects / Q000648:ultrastructure; D004249:DNA Damage; D006570:Heterochromatin / Q000187:drug effects* / Q000648:ultrastructure; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D017404:In Situ Hybridization, Fluorescence; D007399:Interphase; D008677:Metaphase; D013937:Thymidine Kinase / Q000235:genetics
D006570:Heterochromatin; D015075:2-Aminopurine; C007300:2,6-diaminopurine; D000228:Adenine Phosphoribosyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase; D013937:Thymidine Kinase; D001374:Azacitidine